Article info

PDF
Response to: Comment on l’Ami et al titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ by den Broeder et al

Authors

  1. Correspondence to Merel J l’Ami, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam 1056 AB, The Netherlands ; m.lami{at}reade.nl
View Full Text

Citation

l’Ami MJ, Krieckaert CLM, Nurmohamed MT, et al
Response to: Comment on l’Ami et al titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ by den Broeder et al

Publication history

  • Received 3 November 2017
  • Accepted 4 November 2017
  • Published in print 11 November 2017.
  • Published online 13 November 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.